License Agreements - Additional Information (Details) - USD ($)			1 Months Ended			2 Months Ended	3 Months Ended			9 Months Ended
	Jul. 13, 2021	Jan. 12, 2021	May 31, 2021	Mar. 31, 2021	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
License and Other Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue							$ 1,533,000			$ 32,033,000
George Washington
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment									$ 500,000
Percentage of royalty on net sales										6.00%
Percentage of payments received from sublicensee										15.00%
Royalty payments							500,000	$ 300,000		$ 3,700,000	$ 1,200,000
Harvard
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales										5.00%
Percentage of payments received from sublicensee										20.00%
Clinical development and regulatory milestones amount payable										$ 15,100,000
Percentage of minimum royalty rate										4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds										7.50%
Royalty payments						$ 100,000	100,000			$ 1,700,000
Payments related to clinical development and regulatory milestones						0	0			0
Paratek
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales					2.25%
Royalty payments						$ 33,000	100,000			$ 100,000
Claim expiration										2023-10
PAION AG
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment		$ 109,500,000
Upfront cash payment		$ 22,500,000
Percentage of refundable tax withholding		15.00%
Supply agreement term	3 years
Everest Medicines Limited
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional regulatory milestone payments receivable							8,000,000.0			$ 8,000,000.0
Sales milestone payments receivable							20,000,000.0			$ 20,000,000.0
Royalties payable description										Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory.
Royalties payable period after first commercial sale of product										10 years
Milestone payments received				$ 3,000,000.0
Everest Medicines Limited | Commercial Supply Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from upfront payments			$ 6,800,000
Proceeds from upfront technology transfer payment			4,000,000.0
Proceeds from partial prepayment for XERAVA			2,800,000
Additional technology transfer payment receivable by January 30, 2022			$ 1,000,000.0
Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023			110.00%
Deferred revenue							$ 2,800,000			$ 2,800,000
Everest Medicines Limited | Commercial Supply Agreement | License and Other Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue										$ 5,000,000.0